对于治疗耐药双极性抑郁症的卢拉西增强的现实世界结果:回顾性观察分析
Giorgia Porceddu1, Enrico Pessina2, Carlo Ignazio Cattaneo3
1Department of Neurosciences, San Luigi Gonzaga University Hospital, Turin, Italy.
Frontiers in psychiatry
|March 9, 2026
概括
卢拉西通过减少症状,在治疗耐治疗双极性抑郁症 (TRBD) 中显示出短期的有效性. 虽然一般耐受性很好,但需要进一步的研究来提高TRBD患者的缓解率.
科学领域:
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 耐治疗双极性抑郁症 (TRBD) 在患者护理方面存在重大挑战,影响生活质量并增加医疗保健成本.
- 对于TRBD的诊断标准和基于证据的治疗方法存在有限的共识,这突出了对个性化医疗方法的需求.
- 对于异构的TRBD群体来说,确定有效和耐受良好的治疗选择至关重要.
研究的目的:
- 评估卢拉西作为TRBD的辅助治疗的短期有效性和耐受性.
- 探索卢拉西在个性化医疗中针对个体临床概况量身定制干预措施中的潜在作用.
- 评估辅助路拉西对TRBD患者抑郁和焦虑症状的影响.
主要方法:
- 这是一项为期四周的回顾性多中心观察性研究.
- 包括TRBD患者接受现有药物治疗的卢拉西增强剂.
- 使用17项汉密尔顿抑郁症评分表 (HAM-D),年轻狂热评分表 (YMRS) 和汉密尔顿焦虑评分表 (HAM-A) 评估症状严重程度.
主要成果:
- 纳入了60名患者,平均最终的卢拉西剂量为每天51.2毫克.
- 在所有评估的尺度上观察到抑郁和焦虑症状的显著减少.
- 临床反应率为33.3%,缓解率为3.3%. 在68.3%的完成者中,不良事件是轻度至中度的.
结论:
- 卢拉西显示出作为TRBD的有效和一般耐受良好辅助治疗的潜力.
- 低缓解率表明需要进一步调查和优化治疗策略.
- 卢拉西可以支持精密精神病学中的个性化治疗方法,用于难以治疗的双极性抑郁症.
相关概念视频
01:24Mania and Antimanic Drugs: Overview
719
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
719
01:26Psychosis: Goals of Pharmacotherapy
646
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
646
01:28Drug Therapy
360
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
360
01:28Psychosis and Antipsychotic Drugs: Overview
1.1K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.1K
01:23Antidepressant Drugs: MAOIs and Other Agents
1.1K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K
01:30Bipolar Disorder
1.2K
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
1.2K